[go: up one dir, main page]

MX2012007325A - Capsula de abt-263. - Google Patents

Capsula de abt-263.

Info

Publication number
MX2012007325A
MX2012007325A MX2012007325A MX2012007325A MX2012007325A MX 2012007325 A MX2012007325 A MX 2012007325A MX 2012007325 A MX2012007325 A MX 2012007325A MX 2012007325 A MX2012007325 A MX 2012007325A MX 2012007325 A MX2012007325 A MX 2012007325A
Authority
MX
Mexico
Prior art keywords
phospholipid
capsule
abt
pharmaceutically acceptable
glycerides
Prior art date
Application number
MX2012007325A
Other languages
English (en)
Inventor
Ping Tong
Katherine Heemstra
Nathaniel Catron
Deliang Zhou
Eric A Schmitt
Cristina M Fischer
Geoff G Z Zhang
Yeshwant D Sanzgiri
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2012007325A publication Critical patent/MX2012007325A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Una cápsula farmacéutica comprende una caparazón que tiene encapsulado dentro del mismo una solución de líquido de ABT-263 o una sal farmacéuticamente aceptable del mismo en un vehículo substancialmente no etanólico que comprende como excipientes farmacéuticamente aceptables (a) por lo menos un fosfolípido, (b) al menos un agente de solubilización para dicho al menos un fosfolípido, seleccionado del grupo consistente de glicoles, glicéridos, y mezclas de los mismos, (c) al menos un tensioactivo que no es fosfolípido y (d) al menos un antioxidante que contiene azufre. La cápsula es útil en el tratamiento de una enfermedad caracterizada por la sobreexpresión de una o más proteínas antiapoptóticas de la familia Bcl-2, por ejemplo cáncer.
MX2012007325A 2009-12-22 2010-12-21 Capsula de abt-263. MX2012007325A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28928909P 2009-12-22 2009-12-22
PCT/US2010/061588 WO2011079127A1 (en) 2009-12-22 2010-12-21 Abt-263 capsule

Publications (1)

Publication Number Publication Date
MX2012007325A true MX2012007325A (es) 2012-07-20

Family

ID=44187848

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007325A MX2012007325A (es) 2009-12-22 2010-12-21 Capsula de abt-263.

Country Status (16)

Country Link
US (1) US8927009B2 (es)
EP (1) EP2515883A4 (es)
JP (1) JP5779591B2 (es)
KR (1) KR20120098915A (es)
CN (1) CN102655858B (es)
AU (1) AU2010336518B2 (es)
BR (1) BR112012014499A2 (es)
CA (1) CA2780177A1 (es)
IL (1) IL219921A0 (es)
MX (1) MX2012007325A (es)
NZ (1) NZ599941A (es)
RU (1) RU2550956C2 (es)
SG (2) SG10201500152UA (es)
TW (1) TWI508729B (es)
WO (1) WO2011079127A1 (es)
ZA (1) ZA201203627B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
EP2875814B1 (en) 2012-07-19 2018-08-22 FUJIFILM Corporation Liquid composition containing taxane-based active ingredient, process for producing same, and liquid medicinal preparation
CN102836160A (zh) * 2012-10-10 2012-12-26 武汉大学 一种治疗癌症的组合药物
WO2015006219A1 (en) * 2013-07-08 2015-01-15 Abbvie, Inc. Stabilized pharmaceutical dosage forms comprising atrasentan
CA2933202C (en) * 2014-01-21 2022-05-31 Jason Teckoe Immediate release film coatings containing medium chain glycerides and substrates coated therewith
US11027021B2 (en) * 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
TR201703149A2 (tr) * 2017-03-01 2018-09-21 Univ Yeditepe Kemoterapi̇k i̇laç kompozi̇syonu
JP2022553820A (ja) 2019-11-05 2022-12-26 アッヴィ・インコーポレイテッド 骨髄線維症及びｍｐｎ関連障害をナビトクラクスで処置する際に使用するための投与レジメン

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
AU692506B2 (en) * 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) * 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
WO2002060896A1 (en) * 2001-01-31 2002-08-08 Pfizer Products Inc. Ether derivatives useful as inhibitors of pde4 isozymes
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
DK1471887T3 (da) * 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
KR101002374B1 (ko) * 2002-02-26 2010-12-17 아스트라제네카 아베 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물
AR038628A1 (es) * 2002-03-04 2005-01-19 Novartis Ag Composicion oftalmica
JO2479B1 (en) * 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
SI1575569T1 (sl) * 2002-12-13 2010-12-31 Durect Corp Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7790190B2 (en) * 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
DK1888550T3 (da) * 2005-05-12 2014-09-29 Abbvie Bahamas Ltd Apoptosepromotorer
CN1706371B (zh) 2005-05-27 2010-11-10 沈阳药科大学 一种高效的马蔺子素制剂及其制备方法
EP1933809B1 (en) 2005-10-11 2012-02-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
JP2009513642A (ja) * 2005-10-25 2009-04-02 アボット・ラボラトリーズ 低水溶解度の薬剤を含む製剤およびそれの使用方法
WO2007133796A2 (en) * 2006-05-15 2007-11-22 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
MX2009002422A (es) * 2006-09-05 2009-03-20 Abbott Lab Inhibidores bcl para tratar exceso de plaquetas.
JP2010504974A (ja) * 2006-09-28 2010-02-18 フォリカ，インコーポレーテッド 新しい毛嚢を生成させ毛髪を成長させる方法、キット、及び組成物
WO2008064116A2 (en) * 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
US8536157B2 (en) 2007-04-13 2013-09-17 The University Of Melbourne Non-steroidal compounds
BRPI0817664A2 (pt) * 2007-10-12 2015-03-24 Massachusetts Inst Technology Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
CN101939008A (zh) 2007-12-06 2011-01-05 雅培制药有限公司 用于治疗癌症的abt-263经口组合物
CN101220008B (zh) 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
DE102008040935A1 (de) * 2008-08-01 2010-02-04 BSH Bosch und Siemens Hausgeräte GmbH Küchengerät mit Motordrehzahlanzeige
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2442789A1 (en) * 2009-06-18 2012-04-25 Abbott Laboratories Stable nanoparticulate drug suspension
MX2012003408A (es) 2009-09-20 2012-08-03 Abbott Lab Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2.
CN101798292A (zh) 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备

Also Published As

Publication number Publication date
CA2780177A1 (en) 2011-06-30
KR20120098915A (ko) 2012-09-05
SG181916A1 (en) 2012-08-30
BR112012014499A2 (pt) 2016-08-16
RU2012131408A (ru) 2014-01-27
RU2550956C2 (ru) 2015-05-20
IL219921A0 (en) 2012-07-31
AU2010336518A1 (en) 2012-06-07
CN102655858B (zh) 2015-11-25
JP5779591B2 (ja) 2015-09-16
EP2515883A4 (en) 2013-07-17
SG10201500152UA (en) 2015-03-30
TW201130493A (en) 2011-09-16
TWI508729B (zh) 2015-11-21
EP2515883A1 (en) 2012-10-31
AU2010336518B2 (en) 2014-03-06
US8927009B2 (en) 2015-01-06
US20110159085A1 (en) 2011-06-30
CN102655858A (zh) 2012-09-05
WO2011079127A1 (en) 2011-06-30
ZA201203627B (en) 2013-01-30
NZ599941A (en) 2014-06-27
JP2013515078A (ja) 2013-05-02

Similar Documents

Publication Publication Date Title
MX2012007325A (es) Capsula de abt-263.
MY160603A (en) Stabilized lipid formulation of apoptosis promoter
MX2011011511A (es) Sal de abt-263 y fomas en estado solido de la misma.
BR112012006252A2 (pt) "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
MX349533B (es) Dispersiones solidas que contienen un agente inductor de apoptosis.
UY32599A (es) Formulación oral sólida de abt-263
NZ606194A (en) Isoxazoline derivatives as antiparasitic agents
MX2010003868A (es) Cis-imidazolinas quirales.
PH12015500297A1 (en) Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease
TW200716157A (en) Pharmaceutical formulations and methods of treatment using the same
MX2011012122A (es) Derivados de tiofeno.
MX2012004148A (es) Compuestos de dioxido de iminotiadiazina como inhibidores de la enzima de disociacion de la proteina precursora amiloide en el sitio beta, composiciones, y su uso.
EA200901319A1 (ru) Композиции для назального введения
NZ597248A (en) Solid dispersions containing an apoptosis-promoting agent
MX358435B (es) Capsula de estradiol soluble para insercion por via vaginal.
EA017091B9 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
WO2012168885A9 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
MX2014002362A (es) Formulaciones y formas de dosificacion de fosfolipidos oxidados.
MX2011011526A (es) Formulacion lipida de promotor de apoptosis.
EP2583969A4 (en) NEW RHODANINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS WITH THE RHODANIN DERIVATIVES AS ACTIVE AGENTS
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
PH12013500173A1 (en) Oral controlled release pharmaceutical compositions of blonanserin
MX2010003112A (es) Formas de dosificacion solubles que contienen derivados de cephem adecuados para administracion parenteral.
EA201190282A1 (ru) Фармацевтическая композиция, содержащая тамсулозин
SG165397A1 (en) Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8- aminocaprylic acid

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ABBVIE INC.

FG Grant or registration